6 completed, 2 active not recruiting, 2 recruiting, 1 terminated. 3 Phase 2, 3 Phase 3, 2 Phase 1, 1 Not applicable, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Completed 1 |
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
| Phase 1 | 2 | Completed 1, Recruiting 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 4 | 1 | Unknown 1 |
Follow Hematinics: new trials by email Literature Review of Hematinics trials Research Report on Hematinics
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Incidence, Treatment Patterns, and Outcomes in Transfusion-dependent Lower-risk Myelodysplastic Syndromes in Spain Erythropoiesis-stimulating agents (ESAs), Luspatercept, Lenalidomide - Lower-risk Myelodysplastic Syndromes (TD LR-MDS) | Active not recruiting | Bristol-Myers Squibb | 1300 | 2026-02-02 | 2026-10-01 | |
| To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis Erythropoiesis-Stimulating Agent (ESA), Vadadustat - Anemia of Chronic Kidney Disease | Phase 3 | Completed | Akebia Therapeutics | 353 | 2025-07-24 | 2026-09-04 |
| Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients Roxadustat, Conventional Anemia Management - Kidney Failure, Chronic, Malnutrition-Inflammation Syndrome | Phase 1 / Phase 2 | Recruiting | Mansoura University | 46 | 2025-04-15 | 2025-05-13 |
| Impact of Dapagliflozin in Anemic Chronic Kidney Disease Patients Dapagliflozin (DAPA), Erythropoiesis Stimulating Agent - Chronic Kidney Disease(CKD), Anemia, Kidney Disease, Chronic | Phase 2 | Recruiting | Mansoura University | 80 | 2025-04-01 | 2025-04-02 |
| A Study to Evaluate Treatment Patterns and Effectiveness of Luspatercept Luspatercept, Erythropoiesis-stimulating agent (ESA) - Myelodysplastic Syndromes (MDS) | Completed | Bristol-Myers Squibb | 430 | 2024-11-22 | 2026-09-30 | |
| Vafseo Outcomes In-Center Experience Vadadustat, Erythropoiesis Stimulating Agent - Anemia of Chronic Kidney Disease | Phase 3 | Active not recruiting | USRC Kidney Research | 2200 | 2024-11-20 | 2026-03-10 |
| A Study to Evaluate Luspatercept Treatment Patterns and Outcomes in Erythropoiesis-Stimulating Agents-Naïve Patients With Lower-Risk Myelodysplastic Syndromes in the United States Luspatercept, Erythropoiesis-stimulating agents - Myelodysplastic Syndromes | Completed | Bristol-Myers Squibb | 418 | 2024-08-22 | 2026-02-17 | |
| Hydroxyurea and EPO in Sickle Cell Disease Hydroxyurea, Epoetin Alfa-BioSimilar - Anemia, Sickle Cell, Sickle Cell Disease | Phase 1 / Phase 2 | Completed | Julia Xu | 17 | 2023-05-25 | 2026-01-07 |
| Artificial Intelligence for Optimal Anemia Management in End-stage Renal Disease: The Anemia Control Model (ACM) Trial Anemia Control Model (ACM), IV iron, Erythropoiesis-Stimulating Agent (ESA) - Anemia, End Stage Renal Disease | Not applicable | Terminated | Vifor Fresenius Medical Care Renal Pharma | 88 | 2018-12-10 | 2020-01-07 |
| Effect of Erythropoiesis-Stimulating Agent Therapy in Patients Receiving Palliative Care of Chronic Kidney Disease Erythropoiesis-Stimulating Agent - Anemia of Chronic Kidney Disease | Completed | Chinese University of Hong Kong | 78 | 2017-03-01 | 2019-01-31 | |
| Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell Transplantation erythropoietin, iron supplementation - Anemia, Lymphoma | Phase 4 | Unknown | Peking University | 70 | 2016-10-01 | 2017-01-05 |
| The Clinical Evaluation of the Dose of Erythropoietins Trial Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose. - Kidney Failure, Chronic | Phase 3 | Completed | Giovanni FM Strippoli, MD | 656 | 2009-07-01 | 2016-07-19 |
Anemia (4) · Kidney Failure, Chronic (3) · Myelodysplastic Syndromes (2) · Renal Insufficiency, Chronic (2) · Anemia, Sickle Cell (1) · Bronchiolitis Obliterans Syndrome (1) · Cardiovascular Diseases (1) · Kidney Diseases (1) · Lymphoma (1)
Bristol-Myers Squibb (3) · Mansoura University (2) · Akebia Therapeutics (1) · Chinese University of Hong Kong (1) · Giovanni FM Strippoli, MD (1) · Julia Xu (1) · Peking University (1) · USRC Kidney Research (1) · Vifor Fresenius Medical Care Renal Pharma (1)
United States (5) · Egypt (2) · China (1) · Hong Kong (1) · Italy (1) · Nigeria (1) · Spain (1) · United Kingdom (1)
Giovanni FM Strippoli, MD (1) · Iain Macdougall (1) · Julia Z Xu, MD, MScGH (1) · Noha O. Mansour, Ph.D. (1)
2008 (1)